Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 05 - 25 save search
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)
Published: 2021-05-25 (Crawled : 22:00) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 44.59%
H: 8.41%
C: -29.44%
chinese acquired positive results topline phase 3 trial lefamulin
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
Published: 2021-05-25 (Crawled : 13:15) - globenewswire.com
EYEN | $0.574 8.12% 7.51% 1.4M
|
Health Technology
|
| O: 13.32%
H: 17.16%
C: -9.86%
treatment eye positive results topline phase 3 presbyopia
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.31%
H: 3.23%
C: 0.02%
treatment positive results phase 3 topline
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
APLS | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.31%
H: 3.23%
C: 0.02%
treatment positive results phase 3 topline
EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
EYPT | $17.665 0.94% 0.93% 1.5M
|
Health Technology
|
| O: 0.77%
H: 1.85%
C: -1.3%
treatment eye phase 1 potential trial phase 3 phase 2 dmd enroll
Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma
Published: 2021-05-25 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.2%
H: 0.21%
C: -1.1%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.06%
H: 0.98%
C: -0.34%
treatment china phase 3 trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.